Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-τ

Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting... Our previous study showed that the injection of mouse myeloma V K C K /RM4-IFN-τ cells secreting the fusion protein RM4/IFN-τ to syngeneic BALB/c mice resulted in tumor regression in 70% of mice after tumor inoculation. In this study, the V K C K /RM4-IFN-τ cell line was used to characterize the protective immunity subsequent to tumor inoculation. Our histologic findings demonstrated that, in the primary response to V K C K RM4-IFN-τ inoculation, tumor regression is associated with macrophage infiltration. This macrophage-dominated regression further leads to a protective immunity against the 2nd challenge of parental V K C K tumor cells. FACS analysis and chromium release assays showed that the majority of T lymphocytes that mediated this anti-tumor immunity were CD8 + cytotoxic T lymphocytes (CTLs). Our animal studies further showed that the V K C K /RM4-IFN-τ cells were able to grow as aggressively as the parental V K C K cells in T lymphocyte deficient nude mice. The protective immunity started 7 days, became complete 10 days following and lasted up to at least 12 months subsequent to the tumor inoculation. The adoptive transfer of T lymphocyte-enriched spleen cells or CTLs also conferred significant protection against tumor growth of parental V K C K cells (p < 0.01). These data thus support the notion that genetically engineered tumor cells secreting IFN-τ may have potential use as tumor vaccines in preventing the development of tumor recurrence and/or metastases following the surgical removal of the primary tumors. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Antibodies IOS Press

Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-τ

Qi, Yumin; Moyana, Terence; Chent, Vue; Xiang, Jim
Human Antibodies , Volume 7 (1) – Jan 1, 1996
Download PDF
6 pages

Loading next page...
 
/lp/ios-press/characterization-of-anti-tumor-immunity-derived-from-the-inoculation-0RCWND7EHO

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 1996 by IOS Press, Inc
ISSN
1093-2607
eISSN
1875-869X
DOI
10.3233/HAB-1996-7103
Publisher site
See Article on Publisher Site

Abstract

Our previous study showed that the injection of mouse myeloma V K C K /RM4-IFN-τ cells secreting the fusion protein RM4/IFN-τ to syngeneic BALB/c mice resulted in tumor regression in 70% of mice after tumor inoculation. In this study, the V K C K /RM4-IFN-τ cell line was used to characterize the protective immunity subsequent to tumor inoculation. Our histologic findings demonstrated that, in the primary response to V K C K RM4-IFN-τ inoculation, tumor regression is associated with macrophage infiltration. This macrophage-dominated regression further leads to a protective immunity against the 2nd challenge of parental V K C K tumor cells. FACS analysis and chromium release assays showed that the majority of T lymphocytes that mediated this anti-tumor immunity were CD8 + cytotoxic T lymphocytes (CTLs). Our animal studies further showed that the V K C K /RM4-IFN-τ cells were able to grow as aggressively as the parental V K C K cells in T lymphocyte deficient nude mice. The protective immunity started 7 days, became complete 10 days following and lasted up to at least 12 months subsequent to the tumor inoculation. The adoptive transfer of T lymphocyte-enriched spleen cells or CTLs also conferred significant protection against tumor growth of parental V K C K cells (p < 0.01). These data thus support the notion that genetically engineered tumor cells secreting IFN-τ may have potential use as tumor vaccines in preventing the development of tumor recurrence and/or metastases following the surgical removal of the primary tumors.

Journal

Human Antibodies – IOS Press

Published: Jan 1, 1996

There are no references for this article.